Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Corticosteroid-induced osteoporosis
Autore:
Adachi, JD;
Indirizzi:
McMaster Univ, St Josephs Hosp, Dept Rheumatol, Hamilton, ON L8N 1Y2, Canada McMaster Univ Hamilton ON Canada L8N 1Y2 ol, Hamilton, ON L8N 1Y2, Canada
Titolo Testata:
INTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINE
fascicolo: 4, volume: 46, anno: 2001,
pagine: 190 - 205
SICI:
1534-892X(200107/08)46:4<190:CO>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MINERAL DENSITY; INFLAMMATORY BOWEL-DISEASE; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; INTERMITTENT CYCLICAL ETIDRONATE; PARATHYROID-HORMONE TREATMENT; STEROID-INDUCED OSTEOPOROSIS; CONTROLLED CLINICAL-TRIAL; PLACEBO-CONTROLLED TRIAL; 2-YEAR FOLLOW-UP; RHEUMATOID-ARTHRITIS;
Keywords:
inflammatory diseases; bisphosphonates; HRT; calcitonin; fluoride; anabolic therapy; calcium-vitamin D; diuretics (thiazides);
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
126
Recensione:
Indirizzi per estratti:
Indirizzo: Adachi, JD McMaster Univ, St Josephs Hosp, Dept Rheumatol, Charleton Ave E,Suite 501,Hamilton, ON L8N 1Y2, Canada McMaster Univ Charleton Ave E,Suite501 Hamilton ON Canada L8N 1Y2
Citazione:
J.D. Adachi, "Corticosteroid-induced osteoporosis", INT J F W M, 46(4), 2001, pp. 190-205

Abstract

Since Harvey Cushing first noted the coexistence of excess cortisol and loss of skeletal mass over 50 years ago, it has been accepted that supraphysiologic doses of corticosteroids cause clinically significant bone loss. Currently, high-dose oral corticosteroids are used to treat people with a variety of medical conditions, including: rheumatic diseases, such as rheumatoid arthritis, polymyalgia rheumatica, systemic lupus erythematosus and vasculitis; inflammatory lung diseases, like asthma; gastrointestinal diseases, such as inflammatory bowel disease and chronic liver disease; skin diseases, in particular pemphigus, and more recently those who have undergone transplantation. Clinically significant bone loss occurs in the vast majority ofpatients exposed to corticosteroids, and fractures at the spine and hip have been reported with corticosteroid use. Between 30 and 50 percent of patients taking long-term corticosteroids will experience fractures. Today, fractures due to corticosteroid-induced osteoporosis may be prevented. A number of well-designed randomized controlled trials have been conducted that demonstrate preservation and, in some instances, actual increases in bone mass with the use of appropriate drug treatment. Some have even demonstrated reductions in fracture risk. As a result, it is extremely important for clinicians to appreciate the very high risk for vertebral fracture, particularly in postmenopausal women on corticosteroids.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 07:22:15